MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD

MaaT Pharma has announced the publication of retrospective data from the CHRONOS study in the "Bone Marrow Transplantation" journal. This study, one of the largest in real-world settings, evaluated outcomes of third-line systemic therapies in 59 patients with steroid- and ruxolitinib-refractory acute GvHD with gastrointestinal involvement. The findings revealed a 29% 12-month overall survival rate and a 37% Day-28 GI-overall response rate, underscoring the limited efficacy of current therapies.

The data are part of MaaT Pharma's marketing authorization application for MaaT013 (Xervyteg®) with the European Medicines Agency (EMA). The CHRONOS study highlights the need for improved treatment options and sets a contemporaneous benchmark for evaluating novel therapies like MaaT013, currently under regulatory review with feedback expected in mid-2026.